Local and intralesional therapy of in-transit melanoma metastases

Journal of Surgical Oncology

Volumn 104, Issue 4, 2011, Pages 391-396

  Testori, Alessandro ^a   Faries, Mark B ^b   Thompson, John F ^c,d   Pennacchioli, E ^a   Deroose, Jan P ^e   Van Geel, Albertus N ^e   Verhoef, Cornelis ^e   Verrecchia, Francesco ^a   Soteldo, Javier ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Melanoma Institute Australia   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e RIJNLAND HOSPITAL   (Netherlands)

Author keywords

electrochemotherapy; intralesional immunotherapy; melanoma in transit metastases

Indexed keywords

BCG VACCINE; BLEOMYCIN; CISPLATIN; IMIQUIMOD; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; THIOTEPA;

BCG VACCINATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DRUG HYPERSENSITIVITY; ELECTROCHEMOTHERAPY; GENERAL ANESTHESIA; HUMAN; IN VIVO STUDY; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LOCAL ANESTHESIA; MELANOMA; METASTASIS; MULTIPLE SCLEROSIS; PACEMAKER; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR VOLUME;

ADMINISTRATION, TOPICAL; ANTINEOPLASTIC AGENTS; CYTOKINES; ELECTROCHEMOTHERAPY; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; LYMPHATIC METASTASIS; MELANOMA; MYCOBACTERIUM BOVIS; RADIOTHERAPY; SKIN NEOPLASMS;

EID: 80052012621     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22029     Document Type: Review

References (43)

1. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
2. Damian DL, Thompson JF:, Treatment of extensive cutaneous melanoma metastases with topical diphencyprone. J Am Acad Dermatol 2007; 56: 869-871. (Pubitemid 46578262)
3. Damian DL, Shannon KF, Saw RP, et al.: Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Austr J Dermatol 2009; 50: 266-271.
4. Berman B, Poochareon VN, Villa AM:, Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Ther Lett 2002; 7: 1-6.
5. Green DS, Bodman-Smith MD, Dalgleish AG, et al.: Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156: 337-345. (Pubitemid 46095963)
6. Coley WB:, The therapeutic value of the mixed toxins of the streptococcus of erysipelas and bacillus prodigiosus in the treatment of inoperable malignant tumors. With a report of 160 cases. Am J Med Sci 1896; 112: 251-281.
7. Morton D, Eilber F, Malmgren R, et al.: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68: 158-163.
8. Rosenberg S, Rapp H:, Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 1976; 60: 419-430.
9. Cohen MH, Jessup JM, Felix EL, et al.: Intralesional treatment of recurrent metastatic cutaneous melanoma: A randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 1978; 41: 2456-2463. (Pubitemid 8375555)
10. Mastrangelo M, Bellet R, Berkelhammer J, et al.: Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 1975; 36: 1305-1308.
11. Sparks F, Silverstein M, Hunt J, et al.: Complications of BCG immunotherapy in patients with cancer. N Engl J Med 1973; 289: 827-830.
12. Faries MB, Foshag LJ, Essner R, et al.: Intralesional BCG immunotherapy in metastatic melanoma: A review of a 30-year experience. San Francisco, CA: American College of Surgeons Clinical Congress; October 16-20, 2005.
13. von Wussow P, Block B, Hartmann F, et al.: Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988; 61: 1071-1074. (Pubitemid 18078593)
14. Radny P, Caroli UM, Bauer J, et al.: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89: 1620-1626. (Pubitemid 37464130)
15. Den Otter W, Jacobs JJ, Battermann JJ, et al.: Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008; 57: 931-950.
16. Fierlbeck G, d'Hoedt B, Stroebel W, et al.: Intralesional therapy of melanoma metastases with recombinant interferon-beta. Hautarzt 1992; 43: 16-21.
17. Paul E, Müller I, Renner H, et al.: Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection. Melanoma Res 2003; 13: 611-617. (Pubitemid 38296899)
18. Fujimura T, Okuyama R, Ohtani T, et al.: Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol 2009; 34: 793-799.
19. Ridolfi L, Ridolfi R:, Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology 2002; 49: 335-339. (Pubitemid 34606546)
20. Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al.: Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: A pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001; 15: 218-223. (Pubitemid 32903899)
21. Si Z, Hersey P, Coates A:, Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996; 6: 247-255. (Pubitemid 26242686)
22. Oratz R, Hauschild A, Sebastian G, et al.: Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003; 13: 59-66. (Pubitemid 36269815)
23. Thompson JF, Hersey P, Wachter E:, Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008; 18: 405-411.
24. Kaufman HL, Kim DW, DeRaffele G, et al.: Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718-730.
25. Bedikian AY, Richards J, Kharkevitch D, et al.: A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010; 20: 218-226.
26. Triozzi PL, Khurram R, Aldrich WA, et al.: Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 2000; 89: 2646-2654. (Pubitemid 32011610)
27. Molenkamp BG, Sluijter BJ, van Leeuwen PA, et al.: Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 2008; 14: 4532-4542.
28. Curigliano G, Spitaleri G, De Pas T, et al.: A dose finding pharmacokinetic study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors. J Clin Oncol 2007; 25: Abstract 3057.
29. Mir L:, Bases and rationale of the electrochemotherapy. Eur J Cancer 2006; 4: 38-44. (Pubitemid 44666530)
30. Sadadcharam M, Soden DM, O'Sullivan GC:, Electrochemotherapy: An emerging cancer treatment. Int J Hyperthermia 2008; 24: 263-273. (Pubitemid 351517159)
31. Gimbel MI, Delman KA, Zager JS:, Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008; 15: 225-232.
32. Larkin JO, Collins CG, Aarons S, et al.: Electrochemotherapy: Aspects of preclinical development and early clinical experience. Ann Surg 2007; 245: 469-479. (Pubitemid 46673144)
33. Moller MG, Salwa S, Soden DM, et al.: Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 2009; 9: 1611-1630.
34. Rudolf Z, Stabuc B, Cemazr M, et al.: Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 1995; 29: 229-235.
35. Glass LF, Pepine ML, Fenske NA, et al.: Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 1996; 132: 1353-1357. (Pubitemid 26386624)
36. Heller R, Jaroszeski MJ, Reintgen DS, et al.: Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83: 148-157. (Pubitemid 28299641)
37. Mir LM, Glass LF, Sersa G, et al.: Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998; 77: 2336-2342. (Pubitemid 28263963)
38. Campana LG, Mocellin S, Basso M, et al.: Bleomycin-based electrochemotherapy: Clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009; 16: 191-199.
39. Quaglino P, Mortera C, Osella-Abate S, et al.: Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215-2222.
40. Testori A, Tosti G, Martinoli C, et al.: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: A novel therapeutic approach. Dermatol Ther 2010; 23: 651-661.
41. Mir L, Gehl J, Sersa G, et al.: Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 2006; 4 (11): 14-25. (Pubitemid 44755132)
42. Byrne CM, Thompson JF:, Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther 2006; 6: 671-678. (Pubitemid 44192884)
43. Burmeister B:, Advances in the treatment of metastatic melanoma through radiotherapy. Asia-Pacific Oncol Hematol 2008; 1: 60-62.